Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menjugate Immunogenicity and Memory Priming in Infants
NCT00311415Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2005
- Primary completion
- Apr 2008
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of meningococcal group c conjugate vaccine in Meningococcal infection caused by serogroup C Neisseria meningitidis, sponsored by Novartis. Started Oct 2005; status: completed.
02
Drugs
meningococcal group c conjugate vaccine
03
Conditions
Meningococcal infection caused by serogroup C Neisseria meningitidis
Beyond the preview
Go deeper on NCT00311415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00311415.